Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | EFTR | Class A Common Stock | Conversion of derivative security | $0 | +9.05K | $0.00 | 9.05K | Aug 25, 2021 | By LWAC D&O LLC | F1, F2 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | EFTR | Class B Common Stock | Disposed to Issuer | $0 | -8.45K | -50% | $0.00 | 8.45K | Aug 25, 2021 | Common Stock | 8.45K | By LWAC D&O LLC | F1, F2, F3 | |
transaction | EFTR | Class B Common Stock | Conversion of derivative security | -9.05K | -100% | 0 | Aug 25, 2021 | Common Stock | 9.05K | By LWAC D&O LLC | F1, F2 |
Id | Content |
---|---|
F1 | On August 25, 2021, pursuant to that certain Agreement and Plan of Merger, dated as of May 26, 2021 (the "Merger Agreement"), by and among the Issuer (f/k/a Locust Walk Acquisition Corp.), Locust Walk Merger Sub, Inc. ("Merger Sub"), and eFFECTOR Therapeutics, Inc. ("Old eFFECTOR"), Merger Sub merged with and into Old eFFECTOR with Old eFFECTOR surviving as a wholly owned subsidiary of the Issuer (the "Merger"). In connection with and upon consummation of the Merger, each of the Issuer's outstanding shares of Class B Common Stock automatically converted into one share of Class A Common Stock. |
F2 | Represents shares held directly by the Sponsor, of which LWAC D&O LLC is a member. |
F3 | Pursuant to an agreement by and between the Issuer and Locust Walk Sponsor, LLC (the "Sponsor"), concurrent with the consummation of the Merger, these shares of Class B Common Stock were forfeited to the Issuer immediately prior to the Merger. |